2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)
Rivera, F, Karthaus, M, Hecht, J.R, Fasola, G, Canon, J.L, Guan, X, Demonty, G, Schwartzberg, L.S
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies
Wainberg, Z.A, Hecht, J.R, Konecny, G.E, Chmielowski, B, Finn, R.S, Martinez, D, Yonemoto, L, Glaspy, J, Slamon, D.J
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
439TiP A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)
Fakih, M.G., Tejani, M., Ren, X., Landes, D., Werneke, S., Curtis, K.K., Hecht, J.R.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (Pta) Guided Intratumoral Tnferade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC)
Farrell, James J, Senzer, N, Hecht, J.R, Hanna, N, Chung, T, Nemunaitis, J, Rosemurgy, A, Javle, M, Reid, T, Posner, M, Macko, J, Chang, K
Published in Gastrointestinal endoscopy (2006)
Published in Gastrointestinal endoscopy (2006)
Get full text
Journal Article
514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Wolpin, B., Hong, D., Spira, A., Starodub, A., Park, W., Sommerhalder, D., Valerin, J., Barve, M., Punekar, S., Pelster, M., Herzberg, B., Azad, N., Aung, K., Hecht, J.R., Cheng, L., Vora, R., Salman, Z., Zhang, Y., Lin, T., Garrido-Laguna, I.
Published in European journal of cancer (1990) (01.10.2024)
Published in European journal of cancer (1990) (01.10.2024)
Get full text
Journal Article
44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy
O'Kane, G.M., Spratlin, J., Oh, D-Y., Rha, S.Y., McWhirter, E., Elimova, E., Kavan, P., Choi, M.K., Kim, D., Goodwin, R.A., Hecht, J.R., Koo, D-H., Halani, K., McAllister, R., Jones, M., Snow, M.D., Lemmerick, Y., Spera, G., Pankovich, J.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study
Pietrantonio, F., Ho, G.F., Su, Y-L., Chen, E.X., Yuan, Y., Voon, P-J., Liang, X., Jonker, D., Muñoz, F. Longo, Hecht, J.R., Chandana, S., Arnold, D., Bhattacharya, R., Curtin, J.C., Maul, S., Iwasawa, R., Chowdhury, S., Schnepp, R.W., Baig, M., Hong, Y.S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database
Takeda, Y., Yamazaki, K., Saltz, L., Douillard, J-Y., Punt, C.J.A., Van Cutsem, E., Bokemeyer, C., Venook, A., Koopman, M., Heinemann, V., Cremolini, C., Hecht, J.R., Schmoll, H.J.E-V., Nakayama, G., Sugihara, K., Oki, E., André, T., Shi, Q., De Gramont, A., Yoshino, T.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
Kyi, C.K., Spira, A., Carbone, D.P., Johnson, M.L., Henick, B.S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J.R., Catenacci, D., Liao, C-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A.R., Goldman, J.W.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors
Hecht, J.R., Peeters, M., Martin Jimenez, M., Pless, M., Cubillo, A., Garcia-Corbacho, J., Mach, N., Digklia, A., Park, H., Subbiah, V., Gorski, K., Anderson, A., Liu, C., Snyder, W., Chesney, J.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy
Berlin, J, Hecht, J.R, Reiner, M, Mullenix, M, Suggs, S, Radinsky, R, Freeman, D, Amado, R.G, Meropol, N.J
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)
Hecht, J.R, Trarbach, T, Jaeger, E, Hainsworth, J, Wolff, R.A, Lloyd, K, Bodoky, G, Borner, M, Laurent, D, Jacques, C
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy
Freeman, D, Juan, T, Meropol, N.J, Hecht, J.R, Berlin, J, van Cutsem, E, Reiner, M, Radinsky, R, Amado, R.G, Peeters, M
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Grothey, Axel, Strosberg, Jonathan R, Renfro, Lindsay A, Hurwitz, Herbert I, Marshall, John L, Safran, Howard, Guarino, Michael J, Kim, George P, Hecht, J R, Weil, Susan C, Heyburn, John, Wang, Wenquan, Schweizer, Charles, O'Shannessy, Daniel J, Diaz, Jr, Luis Alberto
Published in Clinical cancer research (15.01.2018)
Published in Clinical cancer research (15.01.2018)
Get full text
Journal Article
Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
Hecht, J.R., Naing, A., Falchook, G., Patel, M.R., Infante, J.R., Aljumaily, R., Wong, D.J., Autio, K., Wainberg, Z.A., Javle, M., Bendell, J.C., Pant, S., Hung, A., Van Vlasselaer, P., Brown, G., Oft, M., Papadopoulos, K.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
Rivera, F, Karthaus, M., Hecht, J.R., Fasola, G., Canon, J.-L., Koukakis, R., Demonty, G., Schwartzberg, L.
Published in Annals of oncology (01.06.2015)
Published in Annals of oncology (01.06.2015)
Get full text
Journal Article
Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
Hecht, J.R., Naing, A., Falchook, G.S., Patel, M.R., Aljumaily, R., Wong, D.J., Autio, K.A., Wainberg, Z.A., Javle, M., Bendell, J., Pant, S., Hung, A., Oft, M., Leveque, J., Papadopoulos, K.P.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
Hecht, J.R., Raman, S.S., Chan, A., Kalinsky, K., Baurain, J.-F., Jimenez, M.M., Garcia, M.M., Berger, M.D., Lauer, U.M., Khattak, A., Carrato, A., Zhang, Y., Liu, K., Cha, E., Keegan, A., Bhatta, S., Strassburg, C.P., Roohullah, A.
Published in ESMO open (01.04.2023)
Published in ESMO open (01.04.2023)
Get full text
Journal Article
Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial
Chu, M.P., Hecht, J.R., Slamon, D., Fontaine, A., King, K., Koski, S., Mulder, K., Hiller, J. Price, Scarfe, A., Spratlin, J., Bang, Y., Hoff, P.M., Sobrero, A., Qin, S., Afenjar, K., Houe, V., Huang, Y.J., Khan-Wasti, S., Chua, N., Sawyer, M.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
620PDPROTON PUMP INHIBITOR (PPIS) THERAPY MAY IMPAIR CAPECITABINE (CAPE) EFFICACY IN METASTATIC GASTROESOPHAGEAL CANCER (GEC), RESULTS FROM THE TRIO-013/LOGIC TRIAL
Chu, M.P., Hecht, J.R., Slamon, D., Fontaine, A., King, K., Koski, S., Mulder, K., Hiller, J. Price, Scarfe, A., Spratlin, J., Bang, Y., Hoff, P.M., Sobrero, A., Qin, S., Afenjar, K., Houe, V., Huang, Y.J., Khan-Wasti, S., Chua, N., Sawyer, M.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article